Dicomit is an antiepileptic drug mainly used to treat seizures in patients with Dravet syndrome (severe myoclonic epilepsy), usually used as an adjuvant therapy in combination with other antiepileptic drugs.

1. Basic information of the drug

(1) Drug category: Belonging to antiepileptic drugs, specifically gamma aminobutyric acid (GABA) modulators.

(2) R&D company: Initially developed by Biocodex in France, it was first approved in France in 1998.

(3) Administration method: Oral suspension or tablet, the dosage should be adjusted according to the patient's weight.

2 main treatments for diseases

(1) Dravet syndrome: Used as adjuvant therapy for epileptic seizures in Dravet syndrome patients aged 2 years and above.

(2) Refractory epilepsy: severe cases of epilepsy with poor response to traditional antiepileptic drugs.

3 mechanisms of action

(1) GABA regulation: exerts antiepileptic effects by enhancing GABA mediated inhibitory neurotransmission.

(2) Sodium channel blockade: may reduce neuronal abnormal discharge by inhibiting voltage dependent sodium channels.

4 Clinical efficacy

(1) Reduce seizure frequency: Clinical trials have shown a significant reduction in seizure frequency in patients with Dravet syndrome.

(2) Long term maintenance effect: Continuously maintaining antiepileptic effects during long-term treatment and improving patients' quality of life.